



GlaxoSmithKline

GlaxoSmithKline
Jean-Pierre Garnier, Ph.D.
Chief Executive Officer

One Franklin Plaza
P.O. Box 7929
Philadelphia, PA
19101 7929

Tel. 215 751 5810
Fax. 215 751 6546
www.gsk.com

June 30, 2004

The Honorable Henry A. Waxman
United States House of Representatives
Committee on Government Reform
2157 Rayburn House Office Building
Washington, DC 20515-6143

Dear Representative Waxman:

Thank you for your letter. It is very important to me to hear your concerns about something we both consider so important. I have great respect for your concerns and want to be immediately responsive to your request.

GlaxoSmithKline is an important partner in the global battle to fight HIV/AIDS and is the world leader in collaborative clinical research trials to lessen the burden of this disease not only on the US but all persons infected with this dreaded virus. The study to which you refer in your letter of June 30, 2004, ACTG 5175, was originally designed to address scientific questions of immediate importance to the care of persons living with HIV/AIDS in the resource-poor setting. For that reason it had received GSK's support. Unfortunately, in mid-2003 the study was significantly and unilaterally modified by the ACTG to a more experimental design that we deemed less relevant to the AIDS crisis in the developing world.

At your request, however, we are happy to discuss the trial again with ACTG. To once again show our commitment to improving the health of HIV positive people in the developing world, we will provide the appropriate GSK HIV medicines for the developing world subjects at our preferential prices.

I know you want to improve the health of people in developing countries, as do we. I look forward to working with you as this progresses.

Sincerely,